

## Freedom of Information Request - FOI2024/006

16 April 2024

**Thank you for your Freedom of Information request.**

Question 1. How many patients were treated in the last 4 months (December 2023 to March 2024) by the dermatology department with each of the following products:

- Abrocitinib
- Acitretin
- Alitretinoin
- Azathioprine
- Baricitinib
- Ciclosporin
- Dupilumab
- Lebrikizumab
- Methotrexate
- Mycophenolate mofetil
- Pimecrolimus
- Phototherapy (UVB or PUVA) - for Atopic Dermatitis only
- Tacrolimus ointment
- Tralokinumab
- Upadacitinib

Question 2. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:

- Age 6-11
- Age 12-17
- Age 18 and above

**I have considered your request and have set out the Trust's response below:**

Products	6 to 17	18 and above	Total Number
Abrocitinib	0	0	0
Acitretin	0	0	0
Alitretinoin	0	0	0
Azathioprine	0	0	0

Baricitinib	0	*less than 6	*less than 6
Ciclosporin	*less than 6	0	*less than 6
Dupilumab	0	59	59
Lebrikizumab	0	0	0
Methotrexate	0	8	8
Mycophenolate mofetil	0	0	0
Pimecrolimus	0	0	0
Phototherapy (UVB or PUVA) - for Atopic Dermatitis only	0	0	0
Tacrolimus ointment	0	0	0
Tralokinumab	0	*less than 6	*less than 6
Upadacitinib	0	*less than 6	*less than 6

\* Please note that the exact number of patients has been withheld and instead a range of below 6 has been provided, as this relates to a low number. Statistically low information can potentially identify individuals' data, especially due to the rural nature and low population of the county. It would be, in my view, possible to identify them if this data were to be provided to you. The data therefore consists of personal data and as such has been withheld under Section 40(2) of the Freedom of Information Act 2000.

Yours sincerely,  
Freedom of Information Officer